WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility

WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility

WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany. The permit successfully demonstrates for the first time that Premier Quality together with Record Speed WuXi Biologics consistently delivered in China can also be applied in global countries.

Prime Minister announces £20m to grow medicines manufacturing in the UK

Prime Minister announces £20m to grow medicines manufacturing in the UK

The Prime Minister will launch the government’s new capital investment fund, the Medicines and Diagnostic Manufacturing Transformation Fund, while visiting North Wales later today. This will open up investment opportunities for medicines manufacturers in England, Scotland and Wales – improving our domestic medicine supply chains and creating thousands of highly skilled jobs in the process.

Lindström India launches India’s first cleanroom facility in Pune

Lindström India launches India’s first cleanroom facility in Pune

Lindström India launched its second line of business, called Cleanroom services in India to ensure the highest quality hygiene, safety and reliability which is most critical to customers in the pharmaceutical, food and electronics industry. Lindström’s cleanroom service ensures hygienic production facilities by providing garments serviced in cleanroom laundries which prevent contaminations during process hereby ensuring complete safety of the products being manufactured.

Fill-Finish Facility Expansion

Fill-Finish Facility Expansion

Emergent BioSolutions Inc. (NYSE:EBS) today announced the beginning of a $50 million expansion to the company’s Camden fill/finish facility located in Baltimore, Md. The multi-year expansion is expected to be completed in 2021, and will significantly increase the company’s contract development and manufacturing capacity, redundancy, and flexibility.

New Aseptic API Line Facility

New Aseptic API Line Facility

The aseptic API line facility, which was officially opened today by AMRI leaders and local officials, was announced in November 2017 and enhances capacity at the site while complementing AMRI’s other aseptic API manufacturing plants in Bon Encontre and Tonneins, France.

Novartis plans acquisition of Advanced Accelerator Applications

Novartis plans acquisition of Advanced Accelerator Applications

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera®

AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain. The US Food and Drug Administration (FDA) has granted priority review to AbbVie’s investigational candidate, elagolix, for the management of endometriosis with associated pain. Endometriosis is characterised by long-term pelvic pain and caused by tissue growth outside of the uterus.

Shingrix Reaches US Approval

Shingrix Reaches US Approval

GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 50 years and older. Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses.